Remicade: Biosimilars And Pricing Pressure Wear On J&J's Blockbuster Brand
Executive Summary
US sales were down 14%, but much of the hit was due to a 2016 price adjustment that was felt across the pharma portfolio, and execs insisted the impact of biosimilars is more moderate than expected.
You may also be interested in...
A US Biosimilar Turning Point Approaches, With Work To Do
2022 will be an important year for biosimilar manufacturers as the market expands into new areas like ophthalmology and insulin, and as the Humira US biosimilar entry nears in 2023.
Can Janssen Revive Its Key Remicade Patent? Federal Circuit Hears Pitch
Oral arguments suggest Janssen may have difficulty getting reversal of district court and patent office rulings that its composition patent is invalid.
Can Janssen Revive Its Key Remicade Patent? Federal Circuit Hears Pitch
Oral arguments suggest Janssen may have difficulty getting reversal of district court and patent office rulings that its composition patent is invalid.